Medical Update: HER2-Positive Metastatic Breast Cancer

Medical Update: HER2-Positive Metastatic Breast Cancer
Rebecca J. Jaslow, MD
Clinical Assistant Professor, Medical Oncology
Thomas Jefferson University

About 20 percent of breast cancers are HER2 positive, or test positive for a protein called human epidermal growth factor receptor 2, or HER2. In this session from our 2019 Conference on Metastatic Breast Cancer, Dr. Jaslow discusses the latest treatment options targeting HER2-positive metastatic breast cancer and research in the pipeline. Hear about side effects of treatments and barriers to getting targeted medicine, as well as ways to overcome those barriers.